Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AstraZeneca
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Long Term Extension Study to Evaluate the Safety and Tolerability of oral Tesaglitazar Therapy in Patients with Type 2 Diabetes Mellitus (GALLEX 4)
The primary objective of this study is to monitor the long-term safety and tolerability of tesaglitazar (0.5-1 mg) versus glibenclamide (2.5-15 mg), with or without other oral anti-diabetic drugs, whe...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
AstraZeneca
Update Il y a 4 ans
Étude SAVANNAH : étude de phase 2, évaluant une traitement associant l'osimertinib et le savolitinib aoprès une premier traitement par osimertinib, chez des patients ayant un cancer du poumon non à petites cellules, EGFRm+/MET+.
SAVANNAH: Phase II Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Country
France
organs
Poumon, type non à petites cellules
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients with Advanced Solid Tumours, Lymphomas and Endometrial Carcinoma
To assess the safety and tolerability of AZD8055 in patients with advanced solid tumours or lymphomas (including 20 patients with endometrial carcinoma in Part B).
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca R&D Södertälje
Update Il y a 4 ans
A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL) in Patients with Schizophrenia
The primary objective is to document the clinical benefit of quetiapine SR after switching from other ongoing antipsychotic treatment, regardless of the reason for the switch.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A 24-Week Randomised, Double-blind, Parallel-group, Multi-centre, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Glimepiride (a Sulphonylurea) in Subjects with Type 2 Diabetes who Have Inadequate Glycaemic Control on Glimepiride Therapy Alone
To assess the efficacy of dapagliflozin compared to placebo as add-on therapy to glimepiride in improving glycaemic control in subjects with type 2 diabetes, as determined by the change in A1C levels ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A 52-week, double-blind, randomised, multi-centre, parallel-group,Phase III study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort® (budesonide/formoterol) Turbuhaler® 160/4.5 μg ‘as needed’ compared with terbutaline Turbuhaler® 0.4 mg ‘as needed’ and with Pulmicort® (budesonide) Turbuhaler® 200 μg twice daily plus terbutaline Turbuhaler® 0.4 mg ‘as needed’
To demonstrate that Symbicort Turbuhaler 160/4.5 μg ‘as needed’ is superior to terbutaline Turbuhaler 0.4 mg ‘as needed’.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca Sweden
Update Il y a 4 ans
A randomised, single-blinded, placebo-controlled, multicentre study to investigate the pharmacodynamic effects of lithium on glycogen synthase kinase-3 (GSK-3) activity in patients with Alzheimer's disease
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A double-blind, placebo-controlled, randomised, parallel-group, phase-II, multi-centre study to assess the efficacy, safety and tolerability of 4 twice daily doses and 2 once daily doses of AZD1981 given as tablets during 12 weeks in asthmatic patients treated with inhaled corticosteroids and long-acting-β2-agonists
The primary objective is to evaluate efficacy of AZD1981 compared with placebo in asthmatic patients treated with inhaled corticosteroids (ICSs) and long-acting β2- agonists (LABAs).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
AstraZeneca
Update Il y a 6 ans
Étude PROfound : étude de phase 3 randomisée visant à comparer la sécurité d’emploi et l’efficacité de l’olaparib à l’enzalutamide ou l’abiratérone acétate chez des hommes ayant un cancer de la prostate métastatique résistant à la castration qui ont eu un échec de traitement avec un nouvel agent hormonal et qui ont des mutations des gènes de réparation de la recombinaison homologue.
Le cancer de la prostate prend naissance dans les cellules de la prostate et il est d’évolution lente, mais il peut se propager à d’autres parties du corps, donnant lieu aux métastases. L’adénocarcino...
Country
France
organs
Prostate
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Long-Term, Post treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies, G-PLUS (GALLANT, GALLEX and ARMOR - Post treatment Long-term follow-Up Study)
To investigate post treatment safety of patients with type 2 diabetes, who received randomized treatment in any of the treatment studies GALLANT, GALLEX or ARMOR by: 1. evaluating medical events and p...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
3
4
5
6
7
8
9
10
11
12
Next